Cancer Endorsement Maintenance
Steering Committee Meeting
May 23-24, 2012

National Quality Forum
Executive Building
1030 15th Street, NW, Suite 900
Washington, DC 20005
(202) 783-1300

AGENDA

Day 1: May 23

8:30am    Continental Breakfast

9:00am    Welcome
Angela Franklin, JD, Senior Director
Stephen Lutz, MD (Chair)

9:10am    Introductions and Disclosure of Interest
Ann Hammersmith, JD

9:20am    Overview of Evaluation Process
Ms. Franklin
Lindsey Tighe, MS, Project Manager

9:30am    Consideration of Candidate Measures (Breast)
• 0219: Post breast conservation surgery irradiation (ACS)
• 0220: Adjuvant hormonal therapy (ACS)
• 0221: Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection (ACS)
• 0559: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or III hormone receptor negative breast cancer (ACS)

Please use the following information to access the conference call line:
Dial-in Number: (855) 226-0347
Event Confirmation Code: 78411449 *please note the confirmation code is different for Day 2
Event Title: Cancer Endorsement Maintenance Steering Committee Meeting
11:30am  Break

11:45am  Consideration of Candidate Measures (Breast continued)
- 1857: Trastuzumab not administered to breast cancer patients when human epidermal growth factor receptor 2 (HER2) is negative or undocumented (ASCO)
- 1858: Trastuzumab administered to patients with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer (ASCO)

12:30pm  NQF Member and Public Comment

12:45pm  Lunch

1:15pm  Consideration of Candidate Measures (Breast continued)
- 1878: Human epidermal growth factor receptor 2 (HER2) testing in breast cancer (ASCO)
- 1855: Quantitative HER2 evaluation by IHC uses the system recommended by the ASCO/CAP guidelines (CAP)
- 0623: History of Breast Cancer – Cancer Surveillance (ActiveHealth Management)
- 0031: Breast Cancer Screening (NCQA)

3:30pm  Break

3:45pm  Consideration of Candidate Measures (Breast, Colorectal)
- 0387: Oncology: Hormonal Therapy for Stage IC Through IIIC, ER/PR Positive Breast Cancer (AMA-PCPI)
- 0391: Breast Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade (AMA-PCPI; CAP)
- 0392: Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade (AMA-PCPI, CAP)

4:45pm  NQF Member and Public Comment

5:00 pm  Adjourn
Day 2: May 24

8:30am  Continental Breakfast

9:00am  Welcome, Recap of Day 1
Dr. Lutz
Ms. Franklin

9:15am  Consideration of Candidate Measures  (Colorectal)
• 0223: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer (ACS)
• 0225: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (ACS)
• 0385: Oncology: Chemotherapy for Stage IIIA through IIIC Colon Cancer Patients (AMA-PCPI)

10:30am  Break

10:45am  Consideration of Candidate Measures  (Colorectal continued)
• 1859: KRAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy (ASCO)
• 1860: Anti-epidermal growth factor receptor monoclonal antibody therapy not received by metastatic colorectal cancer patients with KRAS gene mutation (ASCO)

11:45am  Measure Gaps

12:15pm  NQF Member and Public Comment

12:30pm  Next Steps
Ms. Franklin
Ms. Tighe

12:45pm  Adjourn

Box lunches will be provided for Steering Committee members